The company said it held its April 30, 2026 annual meeting of stockholders, and 1,130,179,690 of the 1,241,222,013 shares entitled to vote were represented in person or by proxy at the start of the meeting, which constituted a quorum.

1. 01

   The company said it held its April 30, 2026 annual meeting of stockholders, and 1,130,179,690 of the 1,241,222,013 shares entitled to vote were represented in person or by proxy at the start of the meeting, which constituted a quorum.

2. 02

   Gilead Sciences said stockholders elected 9 directors. For example, Daniel P. O’Day received 980,597,212 votes for, 50,179,985 against and 4,394,880 abstentions, with 95,008,389 broker non-votes.

3. 03

   The company said stockholders approved the selection of Ernst & Young LLP with 1,046,350,569 votes for, approved the advisory vote on executive compensation with 954,325,805 votes for, and approved the amended 2022 Equity Incentive Plan with 970,290,586 votes for.

4. 04

   The company said a proposal for an independent Board Chair policy failed, with 280,044,780 votes for and 752,716,225 against. A proposal for a report on extended patent exclusivities received 134,042,210 votes for, and a proposal for a report on the risks of ESG and DEI executive compensation metrics received 7,262,421 votes for, and both failed.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.